Trial reportInternational urology and nephrology2026
The effect of testosterone therapy on erectile dysfunction in type 2 diabetic patients.
Trial report in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionErectile dysfunction (ED) is commonly observed in Type 2 diabetic men, affecting approximately 75% of this demographic. Evidence suggests that phosphodiesterase-5 (PDE-5) inhibitors have limited therapeutic effects on progressive ED in men with Type 2 diabetes, indicating the need for alternative treatment lines. This study aims to investigate the effects of testosterone therapy on ED in Type 2 diabetic patients with normal testosterone levels. MATERIALS AND
methodsThis single-blind randomized clinical trial was conducted on Type 2 diabetic men with normal testosterone levels and erectile dysfunction. The control group received standard treatment with tadalafil 20 mg two hours before intercourse. In contrast, the intervention group, in addition to tadalafil, received 250 mg of intramuscular testosterone at 3 points (the start, and at 1 and 2 months afterwards. Informed consent was obtained, and participants were selected based on inclusion and exclusion criteria.
findingsA total of 60 Type 2 diabetic patients with ED were included, with an average age of 50.4 ± 9.7 years. Significant differences were observed between the intervention and control groups in terms of average total testosterone and International Index of Erectile Function (IIEF) scores (P value < 0.01), with the intervention group showing higher averages. These differences were also significant over time (P value < 0.01), indicating improved outcomes concerning the baseline.
conclusionTestosterone therapy in diabetic men led to improvements in sexual desire and ED without adverse effects on liver function.
Indexed as
Identifiers
40610841What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.